ArticleCancers2020
Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS).
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 135 citations in OpenAlex.
- Post-marketing reporting patterns and disproportionality signals of mycophenolate mofetil: a pharmacovigilance study using the FAERS Database.Clinical rheumatology · 2026Article
- Gastrointestinal adverse events related to monoclonal antibodies: A comprehensive evaluation of data from the FDA Adverse Event Reporting System database.Indian journal of pharmacology · 2026Article
- Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission.Haematologica · 2026Review
- Article
- Article
- Article
- Bosutinib-Associated Cardiac Tamponade: Late-Onset Treatment-Emergent Adverse Event-A Case Report.Case reports in cardiology · 2026Article
- Post-marketing safety of tarlatamab in small cell lung cancer based on FAERS and WHO-VigiAccess with SHAP-based interpretable machine learning analysis of immune-related adverse events.Frontiers in pharmacology · 2026Article
- Insights and perspectives into the etiology of TKI-induced cardiotoxicity.ASPET discovery · 2026Article
- Adverse reactions of dasatinib in pediatric acute lymphoblastic leukemia: a retrospective comparative cohort study.Translational pediatrics · 2025Article
- Cardiovascular toxicity from tyrosine kinase inhibitors in chronic myeloid leukemia with severe dilated cardiomyopathy.International journal of hematology · 2025Article
- Real-world safety assessment of tamsulosin based on adverse event analysis from the FAERS database.Scientific reports · 2025Article
- Torsade de Pointes and QT Prolongation Among Antifungal Triazoles: A Real-World, Retrospective, Observational, Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database.Cardiovascular toxicology · 2025Observational
- Cardiovascular toxicities associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a pharmacovigilance study based on FDA adverse event reporting system.International journal of clinical pharmacy · 2025Article
- Asciminib in late-line CML treatment.Blood advances · 2025Article
- KAT7 contributes to ponatinib-induced hypertension by promoting endothelial senescence and inflammatory responses through activating NF-κB signaling pathway.Journal of hypertension · 2025Article
- Oseltamivir-induced hepatotoxicity: A retrospective analysis of the FDA adverse event reporting system.PloS one · 2025Article
- Valproate sodium-associated acute pancreatitis: a case report and systematic analysis of antiepileptic drug adverse events in FAERS.American journal of translational research · 2025Article
- Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database.Frontiers in pharmacology · 2025Article
- Cardiac arrhythmias of BCR-ABL inhibitors with or without triazole antifungal agents: A real-world pharmacovigilance study based on the food and drug administration adverse event reporting system database.SAGE open medicine · 2025Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tyrosine kinase inhibitors (TKIs), the treatment of choice for chronic myeloid leukemia (CML), can be associated to cardiovascular (CV) adverse events (AEs). A case/non-case study was performed using AE reports registered in the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to compare the risk of CV event reports related to TKIs indicated in the management of chronic myeloid leukemia (CML). Disproportionality of CV event-related TKIs was computed using the Reporting Odds Ratio (ROR) as a measure of potential risk increase. Nilotinib accounts for more than half of reported cases related to TKIs. Signal of Disproportionate Reporting (SDR) was found for cardiac failure, ischemic heart disease, cardiac arrhythmias,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.